Home › with Excess of Blasts Refractory Anemia › Texas
with Excess of Blasts Refractory Anemia clinical trials in Texas
7 studies for with Excess of Blasts Refractory Anemia are looking for participants at sites in Texas.
Cities in Texas
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT00801489Luspatercept + Darbepoetin in MDS
- Harold C. Simmons Comprehensive Cancer Center of UT Southwestern, Dallas
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07096297Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT03383575Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Jul 30, 2026 · NCT02727803A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT06680752From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.